All In Biotech

Drug Trial Radar · NCT07536308

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

A Phase 1 Open-Label Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike, A Next-Generation SARS-CoV-2 Booster Vaccine Via Intranasal and Inhalational Routes, in Previously Vaccinated Adults

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

83

Actual

Start

May 26, 2026

Primary completion

Apr 29, 2027

Study completion Nov 1, 2027

Sponsor

Sponsor type
NIH
First posted
Apr 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a primary COVID-19 vaccination series and at least one booster. The study evaluates two dose levels (1×10\^10 viral particles (VP) and 5×10\^10 VP) and two routes of administration (intranasal and inhaled). The trial includes 80 participants across four study arms (20 per arm). The primary objective is to evaluate the safety and reactogenicity of a single dose of OCU500 administered in previously vaccinated healthy adults.

Conditions

  • COVID-19

Interventions

  • OCU500Biological

    OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of abnormal clinical safety laboratory adverse events (AE).Time frame: Through Day 8
  2. Occurrence of adverse events of special interest (AESI).Time frame: Through 6 months post study product administration
  3. Occurrence of medically attended adverse events (MAAEs).Time frame: Through 6 months post study product administration
  4. Occurrence of new-onset chronic medical conditions (NOCMCs).Time frame: Through 6 months post study product administration
  5. Occurrence of serious adverse events (SAEs).Time frame: Through 6 months post study product administration
  6. Occurrence of solicited local adverse events (AEs).Time frame: Through Day 8
  7. Occurrence of solicited systemic adverse events (AEs).Time frame: Through Day 8
  8. Occurrence of unsolicited adverse events (AEs).Time frame: Through Day 29

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The Hope Clinic of Emory University

    Decatur, Georgia

  • University of Maryland, School of Medicine, Center for Vaccine Development and Global Health

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Saint Louis University Center for Vaccine Development

    St Louis, Missouri

  • University of Texas Medical Branch

    Galveston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.